Central Retinal Vein Occlusion

Yes, a central retinal vein occlusion is considered an ophthalmological emergency, even if vision remains partially usable. In practice, it is not a "minute-by-minute" emergency, but it is important to be seen within the days following the onset of symptoms in order to confirm the diagnosis, assess retinal perfusion, and promptly begin management (intravitreal injections, close monitoring). The earlier the macular edema is treated, the better the chances of a favorable visual prognosis.

Recovery depends primarily on the initial severity (ischemic or non-ischemic form), the condition of the macula, and the speed of management. Some patients regain very satisfactory vision for daily life, while others retain a visual deficit (decreased acuity, distortion, reduced contrast). The goal of treatment is to stabilize and improve vision as much as possible, but it is not always possible to return to the situation "before" the episode. This is discussed on a case-by-case basis depending on imaging findings and treatment response.

The risk of CRVO in the fellow eye exists, especially if general risk factors are not corrected (high blood pressure, diabetes, hypercholesterolemia, coagulation disorders, smoking, glaucoma). However, it remains low if these factors are well controlled. This is why an occlusion in one eye should always be accompanied by preventive measures for the fellow eye: regular monitoring of blood pressure and intraocular pressure, vascular workup, healthy lifestyle, and scheduled ophthalmological follow-up even in the absence of symptoms.

A central retinal vein occlusion most often reflects fragility of the retinal venous circulation, in the context of an underlying cardiovascular condition (hypertension, cardiac arrhythmia, diabetes, dyslipidemia, smoking, coagulation disorders, etc.). It is not a stroke in the strict sense, but it can be a marker of an at-risk vascular profile. This is why the ophthalmologist often refers the patient to the primary care physician or cardiologist for a comprehensive workup and potential adjustment of preventive treatments (blood pressure, cholesterol, possible antiplatelet or anticoagulant therapy depending on the case).

It all depends on the level of vision achieved after treatment and the type of occupation. If the fellow eye has good vision, returning to work is often possible, sometimes with some adjustments (lighting, visual breaks, optical aids). For driving, the legal binocular visual acuity thresholds must be met, and contrast perception and visual field must remain sufficient. In some cases, a restriction on night driving or long-distance driving may be recommended. These decisions are made during consultations, based on visual examinations and your day-to-day safety.

Intravitreal injections are performed under local anesthesia with eye drops, under strict aseptic conditions. Most patients describe a brief sensation of discomfort lasting a few seconds, but no real pain. They are indicated when there is significant macular edema and the goal is to limit vision loss. In certain forms with very few symptoms or minimal edema, monitoring alone may be considered, but regular injections remain the cornerstone of treatment for many cases of CRVO. The strategy (frequency, drug, duration) is adjusted according to the OCT findings and tolerability.

A new occlusion in the same eye is uncommon but not impossible, particularly if vascular risk factors are not corrected. However, chronic macular edema may persist or recur, requiring injections over time, sometimes with phases of improvement and relapse. Follow-up is precisely intended to adjust treatment in order to anticipate these reactivations and intervene before significant vision loss occurs. In the long term, controlling general risk factors is just as important as the ocular treatments themselves.

Follow-up includes regular ophthalmological consultations with visual acuity measurement, fundus examination, and macular OCT to monitor edema, perfusion, and the possible development of neovascularization. The frequency is close together during the first months (every 1 to 2 months), then may be spaced out if the condition stabilizes. At the same time, follow-up with the primary care physician, cardiologist, or endocrinologist is essential to control blood pressure, blood sugar, cholesterol, and weight. This dual follow-up (eye and general risk factors) aims to protect long-term vision and reduce the risk of vascular events elsewhere in the body.